

The next frontier in the management of mood disorders: clinical insights and promising advances in psychedelics

Industry session financially supported by GH Research during the 37th ECNP Congress.

🕒 **Sunday 22 September 2024**
17:45 – 18:30

📍 **Brown Hall 1-2**

Programme Outline

Join us in our discussion to explore the current unmet medical needs for the effective management of treatment-resistant depression (TRD). This mini session will explore the clinical insights and promising advances of psychedelics, including GH001 (mebufotenin [5-MeO-DMT]), in addition to other key psychedelic treatments currently being investigated.

Session ID:
IMS09

Session type:
Industry Mini Session

Faculty



CHAIRPERSON

Michael E. Thase

Professor of Psychiatry,
Department of Psychiatry of the
Perelman School of Medicine,
University of Pennsylvania,
U.S.A.



SPEAKER

Jan Ramaekers

Professor of Psychopharmacology
and Behavioural Toxicology,
Faculty of Psychology and Neuroscience,
Maastricht University,
Netherlands



SPEAKER

Wiesław J. Cubała

Professor of Psychiatry,
Medical University of Gdańsk,
Poland



Scan For
More Information